Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study. - Sivakumaran, T.; Mileshkin, L.; Grant, P.; Na, L.; DeFazio, A.; Friedlander, M.; Obermair, A.; Webb, P.M.; Au-Yeung, G. (Gynecologic Oncology, 2020)